Alembic Pharma falls 6% post March quarter results

Alembic Pharma Q4FY21 operational performance was marginally below estimates, largely due to lower traction in US and Domestic Formulation (DF) sales

Shares of Alembic Pharmaceuticals dipped 6 per cent to Rs 948 on the BSE in intra-day trade on Wednesday following a weaker-than-estimated operational performance in the March quarter of the financial year 2020-21 (Q4FY21).

The company’s consolidated earnings before interest, taxes, depreciation and amortization (Ebitda) margins declined 45 basis points (bps) to 26.7 per cent in the March quarter (Q4FY21).

The consolidated adjusted profit after tax (PAT) grew 6.5 per cent year-on-year (YoY) to Rs 251 crore. The company’s Q4 revenues grew 6.1 per cent YoY to Rs 1,280 crore with strong growth in RoW formulations and API segment being partly offset